



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Suzy Charbit et al.

Application No.: 10/507,485

Filing Date: January 31, 2005

Title: ENANTIOMER (-) OF TENATOPRAZOLE AND THE THERAPEUTIC USE THEREOF

Group Art Unit: 1625

Examiner: Margaret M. Seaman

Confirmation No.: 8571

AMENDMENT/REPLY TRANSMITTAL LETTER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Enclosed is a reply for the above-identified patent application.

- ☐ A Petition for Extension of Time is also enclosed.
- ☐ Terminal Disclaimer(s) and the ☐ \$65.00 (2814) ☐ \$130.00 (1814) fee per Disclaimer due under 37 C.F.R. § 1.20(d) are also enclosed.
- ☒ Also enclosed is/are Declaration of George Sachs Pursuant to 37 CFR 1.132, Exhibit A, Exhibit B, and two articles entitled "Goodman & Gilman's The Pharmacologicla Basis of Therapeutics", and "Harrison's Principles of Internal Medicine".
- ☐ Small entity status is hereby claimed.
- ☐ Applicant(s) requests continued examination under 37 C.F.R. § 1.114 and enclose the ☐ \$395.00 (2801) ☐ \$790.00 (1801) fee due under 37 C.F.R. § 1.17(e).
- ☐ Applicant(s) requests that any previously unentered after final amendments not be entered. Continued examination is requested based on the enclosed documents identified above.
- ☐ Applicant(s) previously submitted \_\_\_\_\_  
\_\_\_\_\_  
on \_\_\_\_\_  
for which continued examination is requested.
- ☐ Applicant(s) requests suspension of action by the Office until at least \_\_\_\_\_, which does not exceed three months from the filing of this RCE, in accordance with 37 C.F.R. § 1.103(c). The required fee under 37 C.F.R. § 1.17(i) is enclosed.
- ☐ A Request for Entry and Consideration of Submission under 37 C.F.R. § 1.129(a) (1809/2809) is also enclosed.

- ☒ No additional claim fee is required.
- ☐ An additional claim fee is required, and is calculated as shown below.

AMENDED CLAIMS					
	No. of Claims	Highest No. of Claims Previously Paid For	Extra Claims	Rate	Additional Fee
Total Claims	25	MINUS 30 =	0	x \$50.00 (1202) =	\$ 0.00
Independent Claims	8	MINUS 9 =	0	x \$200.00 (1201) =	\$ 0.00
If Amendment adds multiple dependent claims, add \$360.00 (1203)					
Total Claim Amendment Fee					\$ 0.00
<input type="checkbox"/> Small Entity Status claimed - subtract 50% of Total Claim Amendment Fee					\$ 0.00
<b>TOTAL ADDITIONAL CLAIM FEE DUE FOR THIS AMENDMENT</b>					<b>\$ 0.00</b>

- ☐ A check in the amount of \_\_\_\_\_ is enclosed for the fee due.
- ☐ Charge \_\_\_\_\_ to Deposit Account No. 02-4800.
- ☐ Charge \_\_\_\_\_ to credit card. Form PTO-2038 is attached.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17, 1.20(d) and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.


Respectfully submitted,

BUCHANAN INGERSOLL PC

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

Date: November 7, 2005

By



Melissa M. Hayworth  
Registration No. 45,774



Patent  
Attorney's Docket No. 032013-103

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:	)	
Avraham COHEN et al.	)	Group Art Unit: 1625
Application No.: 10/507,485	)	Examiner: Margaret M. Seaman
Filed: September 13, 2004	)	Confirmation No.: 8571
For: ENANTIOMER (-) OF	)	
TENATOPRAZOLE AND THE	)	
THERAPEUTIC USES THEREOF	)	

**RESPONSE UNDER 37 C.F.R. § 1.111**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In complete response to the Office Action dated August 15, 2005, please amend the above-identified patent application as follows.

**Amendments to the Claims** are reflected in the listing of claims, which begins on page 2 of the Response.

**Remarks** begin on page 7 of this Response.

**Attached** is a declaration of George Sachs, M.D., D.Sc., pursuant to 35 U.S.C. § 1.132.